Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics (ARQT) granted an aggregate 57,000 restricted stock units (RSUs) of its common stock to 11 newly hired employees, effective September 1, 2026, as inducement awards under its 2022 Inducement Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Arcutis Biotherapeutics (ARQT) granted an aggregate 57,000 restricted stock units (RSUs) of its common stock to 11 newly hired employees, effective September 1, 2026, as inducement awards under its 2022 Inducement Plan.
The RSUs vest over four years, with 25% vesting on each annual anniversary of the vesting commencement date, subject to continued employment, and were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Details
News Market Reaction – ARQT
On Sep 8, the first trading day after this news, ARQT closed 2.05% above the previous close. Our momentum scanner recorded 7 alerts for this stock that day. Relative volume reached 7.9x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 8 session.
Key Figures
- Restricted stock units
- 57,000 RSUs
- Granted to newly hired employees
- Recipients
- 11 employees
- Newly hired employees receiving grants
- Grant date
- September 1, 2026
- Date of inducement grant
- Vesting period
- 4 years
- RSU vesting schedule
- Annual vesting
- 25%
- Vests on each annual anniversary
Historical Context
-
Management scheduled a fireside chat at the Morgan Stanley healthcare conference.
-
Arcutis granted restricted stock units and options to newly hired employees.
-
Arcutis reported higher revenue, net income, guidance, and operating cash flow.
-
Christopher Peetz joined the board effective July 15, 2026.
-
Arcutis scheduled its second-quarter results and conference call for August 5.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
vesting financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 57,000 restricted stock units (RSUs) of Arcutis common stock to 11 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 1, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to each employee’s continued employment with Arcutis through the applicable vesting date.
Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company delivering meaningful innovation to address the needs of individuals living with chronic inflammatory skin diseases. Over the past decade, Arcutis has successfully developed a robust portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases, driven by a commitment to solving the most persistent patient challenges in dermatology. Arcutis’ unique dermatology development platform, built on established scientific pathways and coupled with deep clinical dermatology and commercial expertise, enables us to efficiently develop, scale, and deliver our differentiated therapies while advancing a growing pipeline across a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, head of Corporate Communications
Investors
Brian Schoelkopf, head of Investor Relations
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Arcutis Biotherapeutics (ARQT) announce regarding inducement grants?
Arcutis Biotherapeutics announced the grant of an aggregate 57,000 restricted stock units (RSUs) of its common stock to 11 newly hired employees as inducement awards under its 2022 Inducement Plan, with a grant date of September 1, 2026.
How many RSUs did Arcutis (ARQT) grant and to how many new employees?
Arcutis granted a total of 57,000 RSUs of its common stock to 11 newly hired employees as material inducement awards in connection with their commencement of employment.
What is the vesting schedule for the new Arcutis (ARQT) inducement RSUs?
The RSUs will vest over four years, with 25% vesting on each annual anniversary of the vesting commencement date, subject to each employee’s continued employment through the applicable vesting date.
Under which plan and Nasdaq rule were the Arcutis (ARQT) inducement RSUs granted?
The inducement RSUs were granted under the Arcutis Biotherapeutics 2022 Inducement Plan and are disclosed in accordance with Nasdaq Listing Rule 5635(c)(4), which covers equity inducement awards for new employees.
When is the grant date for the new Arcutis (ARQT) inducement RSUs?
The grant date for the newly issued inducement RSUs is September 1, 2026, as approved by the Compensation Committee of Arcutis’ Board of Directors.